Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 5/20 | 0.49 |
| ▸ | PPARG | P37231 | 4/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 4/20 | 0.47 |
| ▸ | CTSS | P25774 | 4/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | AKT1 | P31749 | 2/20 | 0.46 |
| ▸ | PPARD | Q03181 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23040267 | 1.00 | PPARA (0.49) | PPARAPPARGSYKACECTSK | |
| SCHEMBL26926036 | 1.00 | PPARA (0.49) | PPARAPPARGSYKACECTSK | |
| SCHEMBL26944433 | 0.91 | SYK (0.50) | PPARAPPARGSYKACECTSK | |
| SCHEMBL29270948 | 0.91 | SYK (0.50) | PPARAPPARGSYKACECTSK | |
| SCHEMBL25482409 | 0.91 | SYK (0.50) | PPARAPPARGSYKACECTSK | |
| SCHEMBL23042932 | 0.89 | PPARA (0.49) | PPARAPPARGSYKACECTSK | |
| SCHEMBL26926114 | 0.89 | SYK (0.47) | PPARAPPARGSYKACECTSK | |
| SCHEMBL23040219 | 0.89 | SYK (0.47) | PPARAPPARGSYKACECTSK | |
| SCHEMBL23040218 | 0.89 | SYK (0.47) | PPARAPPARGSYKACECTSK | |
| SCHEMBL28485547 | 0.86 | ACE (0.56) | PPARAPPARGACECTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114302884-B | Substituted pyridopyrimidinone compounds useful as T cell activators | 百时美施贵宝公司 | 2024-06-04 | — | — | CN | disclosed |
| US-20240083898-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | INCYTE CORPORATION | 2024-03-14 | — | — | US | disclosed |
| WO-2023239768-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | INCYTE CORPORATION (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230399342-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | INCYTE CORPORATION | 2023-12-14 | — | — | US | disclosed |
| US-20230151007-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-05-18 | — | — | US | disclosed |
| US-11584747-B2 | Substituted pyridopyrimidinonyl compounds useful as T cell activators | SYNGENE INTERNATIONAL LIMITED (IN) | 2023-02-21 | — | — | US | disclosed |
| EP-4021901-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | Bristol-Myers Squibb Company (US) | 2022-07-06 | — | — | EP | disclosed |
| CN-114302884-A | Substituted pyridopyrimidinone based compounds useful as T cell activators | 百时美施贵宝公司 | 2022-04-08 | — | — | CN | disclosed |
| WO-2021041588-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-04 | — | — | WO | disclosed |
| US-20210061802-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | SYNGENE INTERNATIONAL LIMITED (IN) | 2021-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584747-B2 | Substituted pyridopyrimidinonyl compounds useful as T cell activators | DGKZ, DGKA, DGKG | PPARA 1145/4885PPARG 984/4885SYK 387/4885 |
| US-20210061802-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | PPARA 1145/4885PPARG 984/4885SYK 387/4885 |
| US-20240083898-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | DGKA, DGKI, DGKG | PPARA 1421/4885PPARG 494/4885SYK 2328/4885 |
| US-20230399342-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | DGKA, DGKI, DGKG | PPARA 1421/4885PPARG 494/4885SYK 2328/4885 |
| US-20230151007-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | PPARA 929/4885PPARG 751/4885SYK 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.